These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 23372112)

  • 21. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
    Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
    Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
    Mocroft A; Phillips AN; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren JD;
    Lancet; 2007 Aug; 370(9585):407-13. PubMed ID: 17659333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disparities in Initiation of Combination Antiretroviral Treatment and in Virologic Suppression Among Patients in the HIV Outpatient Study, 2000-2013.
    Novak RM; Hart RL; Chmiel JS; Brooks JT; Buchacz K;
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):23-32. PubMed ID: 25886926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-ART nutritional status and its association with mortality in adult patients enrolled on ART at Fiche Hospital in North Shoa, Oromia region, Ethiopia: a retrospective cohort study.
    Tesfamariam K; Baraki N; Kedir H
    BMC Res Notes; 2016 Dec; 9(1):512. PubMed ID: 27998310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
    Kousignian I; Abgrall S; Grabar S; Mahamat A; Teicher E; Rouveix E; Costagliola D;
    Clin Infect Dis; 2008 Jan; 46(2):296-304. PubMed ID: 18171266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with late antiretroviral therapy initiation in Cameroon: a representative multilevel analysis.
    Ndawinz JD; Chaix B; Koulla-Shiro S; Delaporte E; Okouda B; Abanda A; Tchomthe S; Mboui E; Costagliola D; Supervie V
    J Antimicrob Chemother; 2013 Jun; 68(6):1388-99. PubMed ID: 23391713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda.
    Kiboneka A; Wangisi J; Nabiryo C; Tembe J; Kusemererwa S; Olupot-Olupot P; Joffres M; Anema A; Cooper CL; Montaner JS; Mills EJ
    AIDS; 2008 Nov; 22(18):2493-9. PubMed ID: 19005272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex differences in overall and cause-specific mortality among HIV-infected adults on antiretroviral therapy in Europe, Canada and the US.
    Antiretroviral Therapy Cohort Collaboration (ART-CC)
    Antivir Ther; 2015; 20(1):21-8. PubMed ID: 24675571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.
    Grinsztejn B; Hosseinipour MC; Ribaudo HJ; Swindells S; Eron J; Chen YQ; Wang L; Ou SS; Anderson M; McCauley M; Gamble T; Kumarasamy N; Hakim JG; Kumwenda J; Pilotto JH; Godbole SV; Chariyalertsak S; de Melo MG; Mayer KH; Eshleman SH; Piwowar-Manning E; Makhema J; Mills LA; Panchia R; Sanne I; Gallant J; Hoffman I; Taha TE; Nielsen-Saines K; Celentano D; Essex M; Havlir D; Cohen MS;
    Lancet Infect Dis; 2014 Apr; 14(4):281-90. PubMed ID: 24602844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART.
    Podlekareva D; Mocroft A; Kirk O; Reiss P; Aldins P; Katlama C; Kovari H; Stellbrink HJ; D'Arminio Monforte A; Lundgren JD;
    Scand J Infect Dis; 2008; 40(11-12):908-13. PubMed ID: 18609197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of early mortality in a cohort of HIV-infected children receiving high active antiretroviral treatment in public hospitals in Ethiopia.
    Ebissa G; Deyessa N; Biadgilign S
    AIDS Care; 2015; 27(6):723-30. PubMed ID: 25599414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of all-cause mortality in HIV infected patients is associated with clinical, immunologic predictors and the CCR5 Δ32 deletion.
    Parczewski M; Bander D; Leszczyszyn-Pynka M; Urbanska A; Kaczmarczyk M; Ciechanowicz A; Boron-Kaczmarska A
    PLoS One; 2011; 6(7):e22215. PubMed ID: 21789236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for early mortality after AIDS in the cART era: A population-based cohort study in Italy.
    Suligoi B; Zucchetto A; Grande E; Camoni L; Dal Maso L; Frova L; Virdone S; Boros S; Pappagallo M; Taborelli M; Regine V; De Paoli P; Serraino D
    BMC Infect Dis; 2015 Jun; 15():229. PubMed ID: 26067992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam.
    Cuong do D; Thorson A; Sönnerborg A; Hoa NP; Chuc NT; Phuc HD; Larsson M
    Scand J Infect Dis; 2012 Mar; 44(3):201-8. PubMed ID: 22122590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mortality of HIV infected clients treated with methadone maintenance treatment in Yili Kazakh autonomous prefecture].
    Liu EW; Wang SJ; Liu Y; Liu W; Chen ZS; Li XY; A LY; Wu ZY
    Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Nov; 45(11):979-84. PubMed ID: 22336271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
    Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
    J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
    Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
    J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of AIDS-defining events at initiation of antiretroviral therapy on long-term mortality of HIV/AIDS patients in Southwestern China: a retrospective cohort study.
    Huang Y; Zhou O; Zheng Z; Xu Y; Shao Y; Qin C; Qin F; Lai J; Liu H; Chen R; Ye L; Liang H; Qin X; Jiang J
    AIDS Res Ther; 2020 Jul; 17(1):44. PubMed ID: 32680536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis.
    Murray M; Hogg RS; Lima VD; May MT; Moore DM; Abgrall S; Bruyand M; D'Arminio Monforte A; Tural C; Gill MJ; Harris RJ; Reiss P; Justice A; Kirk O; Saag M; Smith CJ; Weber R; Rockstroh J; Khaykin P; Sterne JA;
    HIV Med; 2012 Feb; 13(2):89-97. PubMed ID: 21819529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.